New vaccines and vaccination strategies - deze pagina niet meer bewerken

We develop new vaccines and vaccine strategies, in particular for poverty-related and so-called 'neglected tropical diseases', by developing and testing new candidate vaccine antigens in animal model. We are an active member of the Leiden Vaccine Group where we are able to move vaccine candidates from discovery to early phase clinical trials. We conduct clinical vaccine studies with controlled infections in volunteers and we assess vaccine delivery and dose sparing of vaccines.

Centre for Controlled Human Infections Leiden

The Center for Controlled Human Infections Leiden has been very successful over the last years and is recognized by WHO, Wellcome Trust and the Bill and Melinda Gates Foundation for exceptional expertise. In our center, under the guidance of Prof. dr. Meta Roestenberg, ongoing studies with malaria, influenza, schistosomiasis and non-toxicogenic Clostridioides intestinal bacteria are being conducted.

Schistomiasis study

Vaccine delivery and dose sparing

Our department plays a central role in the care of patients with COVID19 since the beginning of the pandemic. Under the name BEAT-COVID, 13 LUMC departments have worked together over the past two years to better understand the coronavirus and the response of our immune system. The first results from the BEAT-COVID team have been published in Nature Immunology.

…

Our department plays a central role in the care of patients with COVID19 since the beginning of the pandemic. Under the name BEAT-COVID, 13 LUMC departments have worked together over the past two years to better understand the coronavirus and the response of our immune system. The first results from the BEAT-COVID team have been published in Nature Immunology.

Within the Leiden University Center for Infectious Diseases, Dr. Anna Roukens leads research focussed on the optimisation of vaccine delivery. Under her guidance, fractional dosing regimens for COVID-19 vaccines have been tested with the potential to spare millions of doses of vaccines for pandemic preparedness and global access. In addition, her group investigates the use of novel vaccine delivery strategies, devices and dosing schedules for individuals with impaired immunity such as elderly and immunocompromised patients (e.g. HIV infection or organ transplants). Together with LU-CID best immunologist, she strives to unravel vaccine-induced immunity to more rationally design alternative vaccine delivery strategies in order to serve all of the world's populations.

 

Our department was partner in the VACOPID study, studying the effectivity of vaccination in patients with impaired immunity, and in the COVIH study, investigating the response against covid-=19 vaccines in persons living with HIV.

Research group

More information